Reduced Genomic Diversity, Cognitive Aging, and Dementia Risk

Overview

About this study

The purpose of this study is to determine whether reduced genetic diversity as reflected in lower heterozygosity reduces our adaptability to stressors and thus influences human susceptibility to age-related cognitive decline and dementia.  This will be examined in an established cohort of individuals at genetically defined risk for Alzheimer’s disease based on APOE genotype who have been undergoing longitudinal neuropsychological assessment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 21 years.
  • Cognitively healthy.
  • Previously enrolled in IRBs #1590-00, 1709-97, and 259-99.

Exclusion Criteria:

  • Individuals < 21 years.
  • Anyone who cannot undergo an MRI for standard reasons.
  • Has a pacemaker or other MRI incompatible hardware.
  • Pregnancy.
  • Anyone with known claustrophobia or who were previously unable to tolerate an MRI.  These individuals will still be allowed to contribute DNA for WGS but will not have the MRI.

Eligibility last updated 8/23/21.  Questions regarding updates should be directed to the study team contact.

 

 

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Leslie Baxter, Ph.D.

Closed for enrollment

Contact information:

Deborah Brostrom

(480) 301-6688

Brostrom.Deborah@mayo.edu

More information

Publications

Publications are currently not available